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Alcohol and other drugs of abuse, including psychostimulants and opioids, can induce
epigenetic changes: a contributing factor for drug addiction, tolerance, and associated
withdrawal symptoms. DNA methylation is a major epigenetic mechanism and it is one of
more than 200 methylation reactions supported by methyl donor S-adenosylmethionine
(SAM). Levels of SAM are controlled by cellular redox status via the folate and
vitamin B12-dependent enzyme methionine synthase (MS). For example, under oxidative
conditions MS is inhibited, diverting its substrate homocysteine (HCY) to the trans
sulfuration pathway. Alcohol, dopamine, and morphine, can alter intracellular levels of
glutathione (GSH)-based cellular redox status, subsequently affecting SAM levels and
DNA methylation status. Here, existing evidence is presented in a coherent manner
to propose a novel hypothesis implicating the involvement of redox-based epigenetic
changes in drug addiction. Further, we discuss how a “gene priming” phenomenon can
contribute to the maintenance of redox and methylation status homeostasis under various
stimuli including drugs of abuse. Additionally, a new mechanistic rationale for the use
of metabolic interventions/redox-replenishers as symptomatic treatment of alcohol and
other drug addiction and associated withdrawal symptoms is also provided. Hence, the
current review article strengthens the hypothesis that neuronal metabolism has a critical
bidirectional coupling with epigenetic changes in drug addiction exemplified by the link
between redox-based metabolic changes and resultant epigenetic consequences under
the effect of drugs of abuse.
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INTRODUCTION
Drug and alcohol dependence are debilitating neuropsychiatric
disorders with multi-factorial and complex etiology, associated
with high morbidity and mortality rates. Research over the past
decade has indicated a strong involvement of several molecular
pathways of learning and memory in drug addiction (Nestler,
2002). Stable changes in gene expression under the influence
of drugs of abuse are believed to mediate, at least in part,
the transition from a recreational drug user to a drug addict,
by inducing neuronal adaptations in morphology and synap-
tic plasticity (e.g. long-term potentiation, long-term depression)
(Nestler, 2002). Mounting evidence also indicates that epige-
netic changes, specifically alterations in the pattern of DNA
and histone methylation, can produce long lasting alterations
in gene expression, which affects behavior (Tsankova et al.,
2007; Renthal and Nestler, 2008; Maze and Nestler, 2011).
Indeed, several studies suggest that epigenetic-mediated changes
in gene expression might be an important contributor to drug
tolerance and dependence (Chao and Nestler, 2004; Hyman
et al., 2006; Maze and Nestler, 2011; Robison and Nestler,
2011). Further, the stochastic nature of these periods of gene
sensitization/imprinting might be revealed and even amplified
during drug abstinence, contributing to behavioral withdrawal
symptoms.
The best-understood and most stable epigenetic modification
is methylation of cytosine nucleotides in DNA, which regulates
the transcriptional plasticity of mammalian genomes (Bellizzi
et al., 2013). DNA methylation is carried out by DNA methyl-
transferase (DNMT) enzymes and occurs primarily where a
cytosine (C) precedes a guanine (G) in the DNA sequence
[“C—phosphate link—G—,” or cytosine–guanine dinucleotides
(CpG)], although cytosine methylation at non-CpG positions
has also been reported (Lister et al., 2009). Methylation of DNA
is facilitated and regulated by levels of the methyl donor S-
adenosylmethionine (SAM) and the metabolic pathways which
affect the level of SAM.
An important feature of metabolic processes is the transcrip-
tional regulation of rate-limiting metabolic enzymes, usually
mediated by epigenetic mechanisms. Moreover, the activities of
various enzymes involved in epigenetic modifications, including
DNMTs and histone methyltransferase, are regulated, in part,
by the concentrations of required substrates and cofactors via
feed-back networks (Lee and Workman, 2007). Hence, on one
side, epigenetic changes can affect metabolism by regulating the
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expression of metabolic enzymes (Wolf et al., 2011), while on the
other side, metabolism can disturb epigenetic status, resulting in
changes in gene expression or chromatin structure (Wellen and
Thompson, 2012), which might serve as a compensatory mecha-
nism altering transcription in response to changes in the cellular
environment. Thus, the cell’s metabolic state has complex and
bidirectional integration with the epigenome and transcriptional
regulation, as depicted in Figure 1.
Cellular redox status exerts control over methylation through
the folate and vitamin B12-dependent enzyme methionine syn-
thase (MS), whose activity controls the ratio of the methyl
donor SAM to themethylation inhibitor S-adenosylhomocysteine
(SAH). Under oxidative conditions MS is inhibited, diverting its
substrate homocysteine (HCY) to the transulfuration pathway.
Availability of reduced glutathione (GSH) to donate electrons to
oxidized proteins or lipids determines the intracellular redox sta-
tus, reflected as the ratio of GSH to its oxidized dimeric form
(GSSG). Cysteine, the rate-limiting precursor for the synthesis of
GSH, is made available by two pathways: (1) extracellular uptake
or (2) metabolism of homocysteine via the transulfuration path-
way. However, the transulfuration pathway is limited in adult
cortical neurons and about 90% of all available intracellular cys-
teine, is transported by the excitatory amino acid transporter
3 (EAAT3). Thus, EAAT3 plays an extremely important role in
maintaining redox status and subsequently the activity of more
than 200 methylation reactions, including DNA and histone
methylation (Figure 2).
Opioids, exemplified by morphine, can induce global DNA
hypomethylation and affect retrotransposon transcription levels
by transiently inhibiting cysteine uptake and decreasing intra-
cellular GSH levels (Trivedi et al., 2014a). Here, the current
evidences are compiled to present, how the effects of drugs of
abuse, including alcohol, might commonly impinge on EAAT3-
mediated cysteine uptake by different mechanisms in neuronal
cells, consequently affecting redox status, MS activity, and methy-
lation reactions, including methylation of DNA.
DRUGS OF ABUSE AND GLUTATHIONE-BASED REDOX
HOMEOSTASIS
Although pharmacological actions and downstream signaling
pathways consequent to administration of alcohol and other
drugs of abuse have been described, the nature of biochemi-
cal and metabolic changes contributing to the development of
chronic effects, drug dependence, and withdrawal syndrome are
less known. Alcohol and other drugs of abuse are reported to
alter redox status, and we will focus on their effects on GSH-
based redox status, ROS species, and how these changes affect the
metabolite status for various other elements and key intermedi-
ates of the transulfuration pathway and one-carbon metabolism,
finally affecting SAM levels as well as epigenetic status.
The relationship between drugs of abuse and redox/
methylation status is not coincidental. These drugs act on
pathways, which stimulate attention, awareness, and memory
formation, and these mechanisms stimulate neurons to grow
FIGURE 1 | Bidirectional regulation between transcriptional/epigenetic changes and metabolic homeostasis.
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FIGURE 2 | Methionine synthase acts as a redox switch. Methionine
synthase contains a redox-active methylcobalamin cofactor. Under oxidative
stress, this cofactor becomes oxidized, limiting methionine synthase activity.
Under these conditions, homocysteine can be condensed with serine to form
cystathionine and cysteine, which supports GSH synthesis. Only when
cellular redox state is restored does the favorable GSH/GSSG ratio allow for
the glutathionylation of oxidized cobalamin and methylation of the
glutathionylcobalamin to reactivate the enzyme.
axons and dendrites and form new synapses, as well as induce
axon pruning and synapse retraction (Nestler, 2002; Chao and
Nestler, 2004). However, these synapses, dendrites and axons are
maintained at the cost of an underlying metabolic demand (Xu
et al., 2003). Neurons require ATP to maintain the ion gradi-
ent needed for each action potential sent along the axon, and
that ATP production induces ROS generation and accumula-
tion, representing a demand on antioxidant resources (Deavall
et al., 2012). This can lead to downstream compensatory adaptive
responses in the transulfuration pathway as well as the methy-
lation capacity of the cells, which can induce global epigenetic
changes, increasing transcription of several redox-pathway related
genes including EAAT3 (Trivedi et al., 2014a). This tightly linked
control of antioxidant and neuronal activity might be a way
of ensuring a narrow window of redox potential in the brain.
EAAT3 transcription is linked to redox status through the Keap1-
Nrf2 pathway (Dong et al., 2008; Escartin et al., 2011). When
redox-sensitive cysteine residues on Keap1 become oxidized,
Nrf2 disassociates and causes an increase in the transcription of
EAAT3, but not the other EAATs, although activation of Nrf2
is not the only mechanism increasing the surface expression of
EAAT3 (Escartin et al., 2011). The important role of EAAT3 in
regulating redox status in the human brain is well-recognized,
and its targeting by drugs of abuse can link their addictive
potential to both ROS production and mitigation. However,
other glutamate transporters namely GLT1 (glutamate trans-
porter 1) and xCT− (catalytic subunit of the cystine–glutamate
exchanger), are also reported to be involved in development of
drug addiction. In fact, a decrease in expression of GLT-1 and
xCT in nucleus accumbens (NA) is the most reliable findings
across drugs of abuse and administration protocols found follow-
ing self-administration of cocaine, heroin, alcohol, and nicotine
(Knackstedt et al., 2009; Sari and Sreemantula, 2012; Gipson et al.,
2013; Reissner et al., 2014). Activation of GLT1 byMS-153, a cere-
broprotective agent, can effectively inhibit the induction of con-
ditioned place preference to methamphetamine (MA), cocaine,
and morphine (Nakagawa et al., 2005, 2001). Although, neuro-
circuitry of the glutamatergic system contributes to alcohol and
drug addiction and EAAT3 is classified as a glutamate transporter,
EAAT3 provides about 60–80% of cysteine uptake in neurons and
its influence over redox and epigenetic status is the focus of this
review.
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OPIOIDS
Neuronal cell membranes are composed of phospholipids, gly-
colipids, cholesterol, and proteins, and drugs of abuse, including
opioids, are reported to induce lipid peroxidation (Adibhatla and
Hatcher, 2010) (compromising neuronal membrane integrity)
and oxidative DNA damage, leading to neuronal apoptosis, neu-
rotoxicity, and neurodegeneration. Opioids can induce untoward
effects due to biochemical alterations in target cells (Christie,
2008). Heroin and morphine deplete the antioxidant GSH in
peripheral tissues, and recent reports also document pro-oxidant
effects of morphine in the central nervous system (CNS) (Martin
and Fraser, 1961; Bhat et al., 2004; Guzmán et al., 2006; Xu
et al., 2006; Mannelli et al., 2009; Gutowicz et al., 2011), along
with alterations in antioxidant defense in animals and humans
after administration or withdrawal from these agents (Xu et al.,
2003; Tegeder and Geisslinger, 2004; Mannelli et al., 2009).
Intracerebroventricular administration of morphine is associ-
ated with significantly decreased GSH levels in cerebrospinal
fluid samples, suggesting that the central nervous system would
be vulnerable to damage from oxidative stress (Goudas et al.,
1999). Morphine and heroin tolerance has also been shown to
occur in conjunction with a concomitant decrease in the levels
of EAAT3. Continuous morphine exposure leads to an increase
in the ubiquitinylation and subsequent degradation of surface-
expressed EAAT3 (Mao et al., 2002; Yang et al., 2008a,b). Since
EAAT3 transports cysteine necessary for GSH synthesis, ubiqui-
tinylation, and degradation of EAAT3 might result in decreased
levels of cysteine in the presence of opioids like morphine, as indi-
cated by our recent study. These changes in cysteine uptake are
also translated into changes in the redox andmethylation capacity
of the cell, along with subsequent changes in global DNA methy-
lation (Trivedi et al., 2014b), as well as changes in retrotransposon
methylation (i.e., long interspersed nuclear element 1 (LINE1)
methylation Trivedi et al., 2014a). Further, redox status can also
regulate mRNAmethylation levels as well as mRNA translocation
from nucleus to axonal cones, thereby regulating neuronal mor-
phology and local synaptic mRNA transcript levels (Trivedi and
Deth, 2012).
ALCOHOL
Both clinical and animalmodel studies have demonstrated diverse
effects of chronic ethanol exposure on regulatory enzymes and
metabolites involved in methionine metabolism, indicating ele-
vated homocysteine and SAH levels, accompanied by a reduction
in SAM and GSH levels (Kim et al., 2003; Augustyniak et al., 2005;
Waly et al., 2011). As illustrated in Figure 1, reduced activity of
either MS or CBS can induce elevated levels of homocysteine,
whereas reduced activity of MS or MAT can decrease SAM lev-
els. Since SAHH is reversible, elevated levels have SAH and a
decline in the SAM:SAH ratio could also result from decreased
conversion of SAH to HCY or increased conversion of homo-
cysteine into SAH. Decreased mRNA levels of MS, MAT, and
CBS are reported in studies of liver biopsies from ALD patients,
and concurrent studies also report lower activities of MS, MAT,
and SAHH, along with increased glycine-N-methyltransferase in
chronic ethanol-fed pigs, which correlates to the protein levels of
these enzymes evaluated from the histopathological evaluation
from ALD patients (Villanueva and Halsted, 2004). Decreased
MS activity, with a compensatory rise in BHMT activity has
been reported in ethanol-fed rats (Barak et al., 1987). Both
MAT1A, expressed in adult liver, and MAT2A, expressed in fetal
liver and extra-hepatic tissues, can convert methionine to SAM.
However, MAT1A is susceptible to inactivation by ROS gener-
ated by ethanol-induced elevated CYP2E1, due to nitrosylation
or oxidation of amino acid residues (Sánchez-Góngora et al.,
1997; Ruiz et al., 1998). Interestingly, since SAM promotes pro-
duction of the antioxidant GSH by activation of CBS (Finkelstein
et al., 1975; Prudova et al., 2006), the ethanol-induced and ROS-
mediated inactivation ofMAT1A expression can lead to decreased
GSH production. A previous study from our lab showed that
the ethanol-induced decrease in OHCbl-based MS activity is sec-
ondary to decreased GSH levels resulting in a decreased ability to
synthesize MeCbl (Waly et al., 2011). Additionally, as discussed
later, the ability of MeCbl to completely offset ethanol-mediated
methionine synthase inhibition in brain cortex, but not liver,
suggested tissue-specific differences in the GSH-dependent reg-
ulation of MS activity (Waly et al., 2011).
PSYCHOSTIMULANTS
Amphetamine and MA are highly addictive psychostimulants,
causing potent central nervous system stimulant effects, gener-
ally accompanied by decreased appetite, hypothermia, paranoia,
aggression, and a heightened sense of pleasure (Homer et al.,
2008). Chronic use of MA causes neuronal loss (Ernst et al.,
2000), associated with reductions in dopaminergic and sero-
tonergic function, generally characterized by depletion in the
levels of dopamine transporter (DAT), serotonin transporter
(SERT), serotonin (5-HT), and dopamine (DA) levels (Krasnova
and Cadet, 2009); however, the exact mechanism of action still
remains unclear. Increasing evidence suggests that MA-induced
neurotoxicity involves reactive oxygen species (ROS) and reac-
tive nitrogen species (RNS) (Stephans and Yamamoto, 1994) and
activation of downstream oxidative stress mechanisms. Moreover,
amphetamine and MA formation of superoxides and hyponi-
trites, lead to neurodegeneration (Carvalho et al., 1999, 2001).
These studies also report a significant decline in GSH levels under
the influence of MA (Carvalho et al., 1999, 2001). Dopaminergic
neurons are markedly decreased by early depletion of GSH,
possibly mediated via induction of autophagy, accompanied by
up-regulation of oxidative stress markers, namely 3-NT and 4-
HNE, and N-acetylcysteine (NAC), a precursor for GSH syn-
thesis, rescues MA-induced neurotoxicity and neurodegeneration
(Chandramani Shivalingappa et al., 2012). Hence, alcohol and
other drugs of abuse can induce ROS production and deplete lev-
els of GSH antioxidant, as well as induce changes in SAM levels
and methylation capacity, consequently inducing neuronal adap-
tations to maintain redox and methylation homeostasis, resulting
in chromatin modifications and transcriptional changes as dis-
cussed next.
SAM-DEPENDENT REGULATION OF EPIGENETIC STATUS BY
DRUGS OF ABUSE
Chromatin remodeling is important for mediating transcrip-
tional responses and, in the case of neuronal function, it is
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suggested to contribute to various psychiatric disorders, includ-
ing depression and schizophrenia (Guidotti et al., 2011; Peter and
Akbarian, 2011; Robison and Nestler, 2011). In addition, studies
have also shown that epigenetic changes contribute to behavioral
abnormalities associated with drug addiction (Hyman et al., 2006;
Maze and Nestler, 2011; Robison and Nestler, 2011). For exam-
ple, repeated exposure to drugs of abuse induces long-lasting gene
expression changes in the key brain reward region, the NA (Maze
et al., 2011). There are many review and research articles which
discuss this topic in-depth (refer to papers by Dr. Eric Nestler
and his group Maze and Nestler, 2011; Robison and Nestler,
2011); however, some of the key points related to redox-related
metabolic events will be discussed here.
ALCOHOL
As mentioned previously, DNA/histone methylation can be
directly regulated by SAM levels and indirectly by the pathways
regulating SAM levels. The liver is the main source of SAM (also
known as SAMe and AdoMet) biosynthesis and consumption,
turning over nearly 8 g/day in a normal adult (Mudd et al.,
1980). When SAM is depleted, homocysteine flux shifts toward
remethylation to regenerate SAM, whereas when SAM levels are
high, homocysteine is channeled toward the transulfuration path-
way. Patients with liver disease, including alcohol-mediated liver
damage, have multiple abnormalities in this pathway, resulting
in lower SAM and GSH levels and a higher homocysteine level
(Lu et al., 2002). Additionally, decreased hepatic SAM biosyn-
thesis in ALD can also impact on methylation and antioxidant
defense (Lu et al., 2002), reflected as decreased DNA methylation
and lower GSH levels. This correlation has been demonstrated
in rats fed intragastric ethanol for 9 weeks, which resulted in
decreased hepatic levels of methionine, SAM, GSH, and DNA
methylation by ∼40% (Lu et al., 2000). As noted above, DNA
hypomethylation affects chromatin structure, resulting in altered
gene expression, rendering affected regions more accessible to
DNA-damaging agents (Pogribny et al., 1995). One such exam-
ple is hypomethylation of the c-myc gene and subsequent increase
in c-myc expression, which results in increased genome-wide
DNA strand breaks (Pogribny et al., 1995). Although, the cellu-
lar and molecular mechanisms associated with alcohol tolerance,
dependence, and sensitivity are still not clearly identified, one
of the important pharmacological targets of ethanol in the CNS
is the NMDA receptor (reviewed by Kumari and Ticku, 2000).
Chronic exposure to ethanol elevates brain NMDAR binding
receptor density (Grant et al., 1990; Gulya et al., 1991), as well
as mRNA levels and protein expression of NR2B subunit (Follesa
and Ticku, 1995; Kalluri et al., 1998; Chandler et al., 1999; Bao
et al., 2001). Altered NMDAR-mediated responses are proposed
to contribute to the hyperexcitability and excitotoxicity associated
with ethanol-withdrawal seizures (Thomas and Morrisett, 2000).
Importantly, recent work in mouse cultured cortical neurons
implicates epigenetic modifications as an important regula-
tory mechanism for transcription of NR2B gene. Intronic CpG
methylation changes modulating NR2B gene expression are also
reported under the influence chronic ethanol exposure (Marutha
Ravindran and Ticku, 2004, 2005). Hence, although the work
is in the early stages, it is already evident that alcohol can alter
SAM levels, resulting in altered transcriptional status (e.g. NMDA
receptor) and subsequent behavioral effects (e.g. tolerance and
withdrawal) mediated via epigenetic changes.
PSYCHOSTIMULANTS AND OPIOIDS
Similar to the effects of alcohol, psychostimulants like cocaine and
MA, as well as opiates like morphine and heroin, can affect the
enzymes catalyzing the addition or removal of post-translational
modifications on histone tails (Sanchis-Segura et al., 2009; Maze
et al., 2010, 2011; Jing et al., 2011; Sheng et al., 2011; Rehni
et al., 2012). There are various modifications on histone tails
including methylation, phosphorylation, and acetylation, but for
the purpose of this paper we would focus on methylation of
histone, as it is similar to DNA methylation in being directly reg-
ulated by the levels of SAM and the SAM:SAH ratio. Histone
and DNA methylation levels can regulate normal cognitive func-
tion, and dysregulation has been implicated in several psychiatric
disorders including drug addiction (Tsankova et al., 2007; Peter
and Akbarian, 2011). Dimethylation of histone H3 at lysine 9
(H3K9me2) across the entire genome is catalyzed by enzyme G9a,
a core subunit of a multimeric repressive histone lysine methyl-
transferase (KMT) complex (Fritsch et al., 2010; Shinkai and
Tachibana, 2011). This complex, including G9a, plays a crucial
role in regulating H3K9me2 in cocaine-induced transcriptional
and behavioral plasticity changes, as well as the consequent regu-
lation of susceptibility to chronic stress by prior cocaine exposure
(Maze et al., 2010). Similarly, chronic morphine down-regulates
H3K9me2 in NA across several different classes of repetitive
elements, including LINE1 (Sun et al., 2012). However, the func-
tional implications of this repressive histone methylation under
the influence of opiates are not yet characterized. As indicated
earlier, we also showed that morphine alters the DNA methy-
lation levels in LINE1 retrotransposons (Trivedi et al., 2014a).
Regulation of G9a/H3K9me2 in NA by chronic morphine as well
as cocaine treatment indicates an integral role for G9a as part of
dynamic repressivemachinery in neurons formaintaining normal
patterns of transcription and preventing aberrant gene expression
under the influence of drugs of abuse or in response to negative
environmental stimuli. The pathological down-regulation of this
repressive machinery after chronic exposure tomorphine or other
emotional/environmental stimuli including other drugs of abuse,
can lead to aberrant transcriptional control that contributes to
abnormal synaptic plasticity, behavioral adaptations, and even-
tually symptoms observed in drug addiction (e.g. tolerance and
withdrawal Robison and Nestler, 2011).
NON-CpG METHYLATION AND HETEROCHROMATIN
Changes mediated by drugs of abuse on redox status resulting
in CpG methylation and epigenetic consequences are discussed.
However, previous reports the role of GSH- and SAM-dependent
metabolic regulation on non-CpG sites or non-cytosine methy-
lation, including regulatory role of redox status on the pre-
transcriptional and post-translational modifications of mRNA
including splicing (Trivedi and Deth, 2012). Although mRNA
molecules do contain methylcytosine, the major methylation of
mRNA occurs with the methyl group at the sixth position on
adenosine (m6A) (Pan, 2013). These methyl marks onmRNA can
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regulate the transcriptional state of mRNA. Additionally, methy-
lation marks on RNA-binding proteins, e.g. Fragile-X syndrome
related protein (FMRP), are also regulated by the levels of SAM
(Dolzhanskaya et al., 2006). FMRP is involved in the dendritic
and neurite transfer of mRNA molecules and a deficiency of
FMRP function can lead to altered neurite levels and synaptic
cleft levels of mRNA molecules under the effect of a stimuli, for
example in neurodevelopmental disorders (Darnell et al., 2011)
or under the effects of drugs of abuse (Smith et al., 2014). Similar
to mRNA, the methylation levels of proteins are also regulated by
SAM. For example, protein arginine-methyl transferase (PRMT),
which is an important methyl mark on proteins is under the direct
control of SAM (Trivedi and Deth, 2012) and indirect control
of GSH levels. Previous studies have also shown that drugs of
abuse can induce histone protein methylation changes, including
changes in the heterochromatin transcription levels; e.g. histone
lysine methylation marks on LINE-1 are altered after cocaine
administration (Maze et al., 2011).
The highly critical yet unanswered puzzle in understanding
epigenetic regulation are the factors which determine the prob-
ability of CpG-methylation vs. non-CpG-methylation on a DNA
strand under a specific cellular environment/a set of various stim-
uli, including exposure to drugs of abuse (Arand et al., 2012;
Guo et al., 2014; Medvedeva et al., 2014). An additional layer
of complexity is added by the fact that, a classification pertain-
ing to contributions and sensitivity of the specific gene regions
via epigenetic modifications is not yet characterized. Although,
in general it is believed that the promoter region of a tran-
script is highly sensitive and responsive to epigenetic changes,
recent evidence indicates that intragenic epigenetic regulation
might also be critical for modulating transcriptional status of
a gene (Luco et al., 2011). Almost (∼50%) of CpG islands
(CGIs) are generally present at the promoter regions of anno-
tated genes. However, the other half of CGIs are referred to as
“orphan” CGIs, which reflects the unpredictability whether they
are present within or between characterized transcription units
(Illingworth et al., 2010). Interestingly, the available evidence
suggests that many orphan CGIs are also the sites of transcrip-
tional initiation (e.g. CGIs at the 39 end of the Pomc gene and
exon 2 of the MHC class II I-Ab gene both initiate transcripts of
unknown function whose coding potential is minimal Gardiner-
Garden and Frommer, 1994; Macleod et al., 1998). Several similar
genome-wide analyses have confirmed that a high percentage
of orphan CGIs represent novel promoters (Illingworth et al.,
2010). However, it is possible that some orphan CGIs probably
represent alternative promoters of nearby annotated genes. The
latter is highly critical and indicates a novel role of redox and
methylation status in stimuli-dependent alternative splicing of a
gene variant. Our lab has previously characterized the effects of
redox status on alternative splicing of the MS enzyme (Muratore
et al., 2013), which provided methionine for use in SAM syn-
thesis. Additionally, we also reported that MS is alternatively
spliced in an age-dependent manner as well as in neurodevelop-
mental and neurodegenerative disorders (Muratore et al., 2013;
Hodgson et al., 2013). A number of epigenetic features, includ-
ing DNA methylation, nucleosome occupancy, specific histone
modifications, and protein features, are also strongly associated
with alternative splicing (Luco et al., 2011). Thus, CpG sites can
affect alternative splicing of genes and are under the direct con-
trol of redox status. Although relevant experimental studies are
not performed yet, it is plausible that drugs of abuse modulating
the redox levels might also influence MS activity. For instance, we
have previously reported that opioids alter mRNA levels of theMS
enzyme via regulation of GSH-based redox status (Trivedi et al.,
2014b).
GENETIC MUTATIONS IN REDOX PATHWAYS
Although this paper focuses on the redox and epigenetic changes,
the role of genetic mutations including single nucleotide poly-
morphism (SNPs) in a predisposition to abuse illicit drugs should
be acknowledged. SNPs in gene sequences responsible for methy-
lation machinery and redox regulators are critical for regulating
epigenetic status. Emerging evidence indicates that mutation in
DNMT gene sequence is highly critical for the epigenetic home-
ostasis since these enzymes are directly involved in regulating
DNA methylation levels, including de novo methylation as well
as maintenance methylation. These changes are important during
fetal stages (Potter et al., 2013). Even changes in enzymes main-
taining the SAM levels can also contribute to the development of
a drug addiction phenotype.Methylenetetrahydrofolate reductase
(MTHFR) is involved in maintaining methionine synthase activ-
ity and indirectly regulates SAM levels. SNP ofMTHFR (c.677C>
T) can contribute toward the development of alcohol dependence
and alcohol’s behavioral effects (Saffroy et al., 2008; Shin et al.,
2010; Kobayashi et al., 2012). CBS enzyme, which mediates the
conversion of homocysteine to cystathionine, can contribute to
regulation of epigenetic changes and specifically, SNPs in CBS
and MTRR are reported to induce hypermethylation of promoter
region in lung epithelial cells of individual’s with nicotine addic-
tion (Flores et al., 2012). Morphine and opioid derivatives can
induce hypermethylation of promoter region by mediating effects
on redox status of neuronal cells (Trivedi et al., 2014a,b). Altered
promotermethylation can result either in adaptive transcriptional
levels of mRNA or can lead to priming of the gene as discussed in
a later section. This can further induce subsequent drug expo-
sure or lead to the development of drug addiction or tolerance.
While little work has been performed to qualify this argument,
the authors propose that, since the redox/methylation pathway
is a key mediator of these global changes in genomic tran-
scriptional and translational status, the first immediate response
of cells under any stimuli would revolve around maintain-
ing redox/methylation homeostasis. Hence, the authors reiterate
the previously proposed “holonarchy” of several dynamic and
intertwined processes starting at the bottom and progressing
upward, beginning at protein turnover, post translational mod-
ifications, post-transcriptional regulations, transcription mod-
ifications, epigenetic changes and the highest level would be
GSH-based redox status as a central regulatory switch, not only
regulating CpG-methylation but also non-CpG-methylation on
mRNA and proteins.
GENE PRIMING
Chronic drug exposure alters brain gene expression, further
inducing long-term structural and functional changes in neural
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networks, which result in behavioral symptoms that underlie
compulsive drug taking and seeking (Sanchis-Segura et al., 2009;
Sun et al., 2012). However, the specific mechanisms mediat-
ing the translation of drug-induced gene-expression changes
and synaptic plasticity into persistent neuroadaptations remains
uncharacterized. Intriguingly, preliminary evidence from current
investigations on chromatin modulation in drug addiction mod-
els suggests that epigenetic modifications at individual genes may
not only induce stable changes in mRNA expression of specific
genes, but can also alter the “inducibility threshold” of additional
genes in response to the same, or some other subsequent stimulus
(Robison and Nestler, 2011) (Figure 4). Thus, exposure to drugs
of abuse or other such stimuli primes the genes in a state which
is readily inducible/silenced by subsequent stimuli, although the
steady state levels or baseline expression levels of these genes are
not affected at that point. While these studies are still in the rela-
tively early phase, the latent epigenetic changes can be viewed as
“molecular insults,” which can drastically impinge upon an indi-
vidual’s adaptability, and hence contribute to the behavioral out-
comes especially during tolerance and withdrawal phases. More
importantly, if these long-lasting changes in chromatin structure
are involved in the maintenance of drug addiction behavior, the
ability to reverse the epigenetic signature of an addicted state
would offer a fundamentally new approach for more effective
treatment of drug relapse (Maze and Nestler, 2011).
GENE PRIMING AND DRUG ADDICTION
Priming effects of cocaine and measuring the epigenetic changes
during withdrawal phase or during the subsequent cocaine expo-
sure stages (Levine et al., 2011; Manzanedo et al., 2012; Li et al.,
2014) are recently elucidated. In particular, one study identified
numerous desensitized genes including transcription of ∼10%
of genes induced in the NA by acute cocaine exposure, but not
induced by a subsequent cocaine challenge after a prior period of
chronic exposure to the drug (Maze et al., 2010). On the con-
trary, some genes were also primed or had poised status, i.e.,
transcription of genes was not affected by acute cocaine exposure
but these genes were induced after a chronic course of cocaine, as
evident from approximately three times more genes reported to
be elevated in cocaine-experienced animals. Some of these genes
had decreased G9a and H3K9me2 at the promoter regions, which
suggests a role of epigenetic marks, especially those provided by
G9a, in the gene priming effects toward subsequent drug expo-
sure. Aminor variant of the above gene priming involves exposure
to different drugs, i.e., exposure to a specific drug of abuse fol-
lowed by a subsequent exposure to a different drug of abuse,
and the resulting changes in gene priming, gene expression and
epigenetic changes are characterized. One such study by Levine
et al. (2011) reported that pretreatment of mice with nicotine
increased the response to cocaine, as assessed by addiction-related
behaviors, synaptic plasticity adaptations, transcriptional and
epigenetic changes in the striatum—a brain region critical for
addiction-related behavioral outcomes. It was evident that the
cocaine responses were primed by nicotine, since cocaine’s abil-
ity to induce transcriptional activation of genes (e.g. FosB) via
histone deacetylase (HDAC) inhibition was enhanced by nico-
tine, which induced global histone acetylation in the striatum.
Previous research has indicated that chronic ethanol feeding and
high blood alcohol levels lead to elevated H3K9 acetylation, HAT
activity, and p300 HAT (Bardag-Gorce et al., 2007). Noteworthy
is the fact that the increased H3K9 acetylation, decreased H3K9
trimethylation and DNA methylation showed strong correlations
to changes in gene expression and myeloid body (MB) formation
in drug-primed mice. After withdrawal of the drug, gene expres-
sion changes and MB formation, as well as the ability of SAM to
block this phenomenon, can last up to 4 months (Bardag-Gorce
et al., 2007). This most likely represents an epigenetic memory
phenomenon of gene expression changes under the effect of drugs
of abuse, in this case nicotine, which can further influence the
effect of subsequent drug exposure.
GENE PRIMING AND REDOX STATUS
Changes in glutamate transporter expression, mainly GLT1
but also EAAT3, are well-characterized during morphine with-
drawal (Xu et al., 2003) and reports indicate no changes in
EAAT3-mediated glutamate transport during the withdrawal
period. However, these studies did not measure the effects on
EAAT3-mediated cysteine transport, and further investigations
are needed to define the redox-mediated effects of EAAT3 dur-
ing the withdrawal period (Xu et al., 2003). The latter could be a
period of recovery and compensatory adaptivemechanism during
which cells undertake recalibration from the previous insults or
stimuli including chronic drug exposure (Christie, 2008). Further,
the ability tomaintain or restore redox homeostasis might include
underlying changes in gene expression mediated via epigenetic-
modulation of gene transcription in response to various stimuli,
including drugs of abuse (Mao et al., 2002; Xu et al., 2003;
McClung et al., 2005; Christie, 2008; Robison and Nestler, 2011;
Schwarz et al., 2011). However, we propose that an absence of
these stimuli can render the adaptive changes excessive, leading to
a plethora of compensatory mechanisms which could potentially
result in a switched homeostasis in the opposite direction (Xu
et al., 2003, 2006; McClung et al., 2005). Thus, redox-responsive
adaptive regulation of epigenetic status might exhibit opposite
changes during sustained drug exposure vs. drug withdrawal
states and contribute to the observed symptoms (Figure 3).
GENE PRIMING AND DRUGWITHDRAWAL
While gene transcription changes during the withdrawal period
have been studied (Spijker et al., 2004; Xu et al., 2006; Christie,
2008), epigenetic mechanisms underlying these changes have
not been thoroughly investigated and involvement of changes in
redox status in epigenetic and gene transcription changes needs
to be explored further. Preliminary in vivo results indicate that
EAAT3 and GSH levels are affected during withdrawal period
(Mazei-Robison and Nestler, 2012). Figure 3 depicts a proposed
mechanistic scheme, illustrating contrasting changes in EAAT3-
mediated cysteine uptake and redox status during initial drug
exposure vs. the withdrawal-related washout period, which can
lead to reciprocal changes in gene expression. The key aspect is
that adaptive mechanisms operate to maintain redox equilibrium
in a homeostatic range. Thus, the redox sensitivity of methylation
allows epigenetic regulation of gene transcription to be responsive
to the presence of drugs that alter redox status. Since epigenetic
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FIGURE 3 | Effect of in vitro washout on redox equilibrium. Inhibition of
cysteine uptake can alter cellular redox potential, resulting in adaptive
changes in gene expression via epigenetic effects, which restore the redox
equilibrium. However, in the absence of opioids during the washout
phenomenon, these adaptive changes can lead to increased cysteine uptake
as well as intracellular redox potential. A subsequent drug exposure with
same or different drugs of abuse might also induce changes in the redox
equilibrium further affecting the transcriptional regulatory mechanisms.
effects can be very long-lasting, such changes in transcription
serve to extend the consequences of acute drug use and drug
withdrawal far beyond the actual period of drug exposure, repre-
senting an epigenetic memory of drug abuse. Indeed, some genes
involved in compensatory adaptive changes might display gene
priming, reflecting graded levels of epigenetic regulation, and
transcription-based changes in protein abundance might mod-
ify the redox-regulated pathways indicated in Figure 2. Recent
advancements (Anker and Carroll, 2011; Robison and Nestler,
2011; Schwarz et al., 2011; Feng and Nestler, 2013; Giannotti
et al., 2014; Li et al., 2014) clearly indicate the potential value of
investigating the variousmechanisms thatmodulate the reversible
transitions between chromatin states under the influence of drug
exposure, including gene priming and desensitization.
REDOX REPLENISHERS
Recognition of the effects of drugs of abuse on redox and
methylation capacity of neuronal cells opens a new therapeutic
avenue, which can potentially be exploited to treat or prevent
the symptoms associated with drug tolerance and withdrawal;
indeed, this is already taking place (Ronis et al., 2005; LaRowe
et al., 2006; Chandramani Shivalingappa et al., 2012). Not only are
the enzymes and transporters involved in these pathways poten-
tial drug targets, but small molecules and metabolites which aug-
ment antioxidant status and methylation capacity could regulate
behavioral endpoints under the influence of chronic drug expo-
sure (Tian et al., 2012; Anier et al., 2013; McClure et al., 2014).
Such agents could act to restore epigenetic status to normal and
potentially inhibit the effects of drugs of abuse. In consideration
of the above hypothesis, redox-based interventions which replen-
ish antioxidant homeostasis might be useful for abrogating the
effects of drugs of abuse on redox-state and methylation capacity,
and could be a potential therapeutic strategy for disorders related
to illicit drug use.
NAC is the acetylated precursor of L-cysteine, and it protects
the amino acid from oxidation in the alimentary tract. NAC is
deacetylated after absorption, increasing the levels of intracellu-
lar L-cysteine for the synthesis of GSH. NAC can cross the blood
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FIGURE 4 | Gene priming. Epigenetic mechanisms mediate gene
priming and desensitization under the influence of drugs of abuse,
and that many of these changes are latent, meaning that they are
not reflected by stable changes in steady-state mRNA levels. Instead,
these changes would induce subsequent changes in chromatin
structure, such that a later drug administration/washout would induce a
given gene to a greater (primed) or lesser (desensitized) extent based
on the epigenetic modifications induced by previous chronic drug
exposure. A, acetylation; M, methylation; P, phosphorylation; pol II,
RNA polymerase II.
brain barrier and studies show that neuronal cell cultures synthe-
size GSH in proportion to supplied NAC concentrations (Dodd
et al., 2008). Due to NAC’s neuroprotective action in brain, it has
considerable therapeutic potential in treatment of psychiatric dis-
orders like schizophrenia (Lavoie et al., 2008) and bipolar disorder
(Dean et al., 2011). NAC is also used clinically for symptomatic
treatment of alcoholic patients, cocaine, and heroin abusers
(Baker et al., 2003;Mardikian et al., 2007; Zhou and Kalivas, 2008;
Ferreira Seiva et al., 2009; Chandramani Shivalingappa et al.,
2012). Rodent studies show that ethanol-induced oxidative stress
and increased lipid peroxidation can be reversed by NAC intake
(Ronis et al., 2005). Several studies measuring oxidative stress
status also confirm tha, NAC co-administered with cocaine can
prevent a cue-induced desire and relapse to drug craving (Zhou
and Kalivas, 2008; Reichel et al., 2011). Several mechanisms have
been proposed to account for the actions of NAC in preclinical
models of addiction, but this remains unclear. After 1 week of
cocaine exposure followed by three subsequent weeks of with-
drawal, an IP injection of NAC can recover the decreased basal
extracellular glutamate levels in the NA of the cocaine-treated rats
(Baker et al., 2003). It is noteworthy that when the Xc− trans-
porter is inhibited, the NAC-induced recovery of extracellular
glutamate levels in NA is also inhibited, indicating that the Xc−
system may be important in the neurobiological mechanisms of
drug addiction (Kim et al., 2003). Moreover, these results sug-
gest that NAC can potentially induce recovery of down-regulated
Xc− and GLT-1 function (Dodd et al., 2008; Knackstedt et al.,
2009; Reissner et al., 2014). This would normalize glutamate
homeostasis, which is important for long term potentiation and
memory formation and is implicated in drug addiction, especially
drug tolerance and withdrawal (Knackstedt et al., 2009, 2010;
Knackstedt and Kalivas, 2009). Indeed, knockdown of GLT-1 in
the NA interferes with the ability of NAC to inhibit reinstatement
of cocaine self-administration and this effect was blocked by a
mGluR5 antagonist, suggesting that increased glutamate plays an
essential role (Reissner et al., 2014; Scofield and Kalivas, 2014).
In addition to protecting brain cells against oxidative stress, GSH
also enhances NMDA receptor response to glutamatergic stimu-
lation, indicating that glutamatergic signaling could potentially
be regulated in response to NAC administration (Dean et al.,
2011; Penugonda and Ercal, 2011; Schmaal et al., 2012; McClure
et al., 2014). NAC is reported to prevent relapse behaviors, reduc-
ing drug-associated cues-, cocaine-, and heroin-priming-induced
reinstatement after extinction as well as following abstinence
protocols (Baker et al., 2003; LaRowe et al., 2006; Dean et al.,
2011; Reichel et al., 2011). In addition, even the hangover effects
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produced by a large ingestion of alcohol can be reversed by NAC
(Ronis et al., 2005), the mechanism for which is still unknown.
A different approach is provided by ceftriaxone, a beta-lactam
antibiotic, which up-regulates both GLT-1 and xC− (Alhaddad
et al., 2014b; Rao and Sari, 2014), which is associated with
decreased ethanol consumption by rats with an alcohol pref-
erence (Sari et al., 2013; Alhaddad et al., 2014a). MS-153, a
synthetic agent, that increases GLT-1-mediated glutamate trans-
port (Shimada et al., 1999), can decrease alcohol (Alhaddad
et al., 2014b), morphine, cocaine, and amphetamine consump-
tion (Nakagawa et al., 2001, 2005). A recent study found that
MS-153 up-regulates GLT-1 levels in NA, but not in the prefrontal
cortex (Alhaddad et al., 2014b). Taken together, these studies indi-
cate that modulation of glutamate and/or cysteine/cystine status
holds potential for treatment of drug abuse.
Cobalamin is the cofactor of methionine synthase, which
accepts a methyl-group from 5-methyltetrahydrofolate (5-
MTHF) and adds it to homocysteine to formmethionine. During
oxidative stress Cbl(I), the oxidation state of cobalamin that
readily forms methylcobalamin (MeCbl), will oxidize to Cbl(II),
which cannot be methylated leading to oxidative stress which
inhibits MS activity. Such oxidation of cobalamin represents a
FIGURE 5 | Summary: Redox-based epigenetic signaling. Drugs of
abuse alter cysteine uptake, affecting GSH synthesis, which shifts redox
status and the reducing potential. This shift affects methionine synthase
(MS) activity further affecting the probability of DNA methylation i.e.,
epigenetic changes, subsequently inducing changes in gene transcription or
gene inducibility. If a repeated stimuli occurs, it results in altered gene
transcription. This eventually affects the protein expression and
consequently neuronal functionality and phenotype. Dotted line indicates
that, neuronal activity can also redox status by altering the levels of ROS
produced.
redox-sensitive switch for controlling the methylation cycle, and
MeCbl regulates MS activity (Deth et al., 2008). Provision of
exogenous MeCbl can increase MS activity and sustain a higher
level of methylation. During oxidative stress, MS is inhibited
to prevent HCY conversion to methionine, shifting HCY to the
transulfuration pathway for synthesis of GSH so as to maintain
cellular antioxidant defenses against oxidative stress (Lu et al.,
2000; Muratore et al., 2013). Restoration of adequate GSH lev-
els promotes formation of GSCbl and MeCbl, leading to MS
reactivation. Hence, drugs of abuse decrease GSH level, compen-
satory mechanisms can potentially lead to decreased synthesis of
methionine from HCY and an increase of HCY flux toward tran-
sulfuration and the maintenance of GSH levels. This decrease in
MS activity induces a decrease in SAM and reduces methylation
capacity, causing global DNA (Benzecry et al., 2004; Muratore
et al., 2013) and histone hypomethylation. The addition ofMeCbl
could potentially prevent these effects by promoting MS activ-
ity, abrogating the usual redox-dependent epigenetic changes and
potentially preventing the epigenetic memory induced under the
effects of drug exposure as well as drug-mediated transcriptional
and behavioral changes. To our knowledge, no studies have been
conducted to identify or characterize the effects of MeCbl on drug
addiction, or withdrawal phenomenon, and hence, it is a novel
therapeutic avenue remaining to be explored.
CONCLUSION
Based on the observations from the above studies, we pro-
pose a novel redox-based epigenetics mechanism contributing
to drug addiction (Figure 5). The resultant stochastic nature
of changes in the chromatin structure emphasizes the research
needed to identify specific set of genes, which are altered at the
steady state mRNA levels as well as those genes which are epi-
genetically primed, during drug exposure. Altered redox home-
ostasis contributes as a driving force to mediate these changes.
Furthermore, focused research is also needed for redox-based or
methylation-based interventions, which can potentially be used to
reverse the effects of drugs of abuse and used for drug addiction
treatment.
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